67319-76-0

Usage

InChI:InChI=1/C7H13N3/c8-3-1-2-5-10-6-4-9-7-10/h4,6-7H,1-3,5,8H2

Upstream product

• 72338-63-7 4-imidazol-1-ylbutyronitrile 
• 93668-30-5 2-[4-(1H-imidazol-1-yl)butyl]-1H-isoindole-1,3(2H)-dione 

Downstream Products

• 100485-40-3 N-<(1H-Imidazol-1-yl)butyl>benzoylamide 
• 107962-04-9 N-<4-(1H-imidazol-1-yl)butyl>-6-<<2-bromo-4-(1-methylethyl)phenyl>amino>-3-pyridinecarboxamide 
• 88939-84-8 N-<4-(1H-imidazol-1-yl)butyl>-2-(1-methylethyl)-11-oxo-11H-pyrido<2,1-b>quinazoline-8-carboxamide 
• 107962-03-8 N-<4-(1H-imidazol-1-yl)butyl>-6-<(4-isopropylphenyl)-amino>-3-pyridinecarboxamide 
• 154965-43-2 Dithiophosphoric acid O-[(2R,3S,5R)-2-[[3-(4-imidazol-1-yl-butylcarbamoyl)-phenyl]-bis-(4-methoxy-phenyl)-methoxymethyl]-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-3-yl] ester S,S'-diphenyl ester 
• 154965-39-6 3-[[(2R,3S,5R)-3-Hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-2-ylmethoxy]-bis-(4-methoxy-phenyl)-methyl]-N-(4-imidazol-1-yl-butyl)-benzamide 
• 110552-68-6 2-Amino-5-chloro-N-(4-imidazol-1-yl-butyl)-benzamide 
• 93668-23-6 4-Bromo-N-(4-imidazol-1-yl-butyl)-benzamide 
• 93668-22-5 3,4-Dichloro-N-[4-(1H-imidazol-1-yl)butyl]benzamide 
• 93668-24-7 4-Chloro-N-(4-imidazol-1-yl-butyl)-benzamide 

Relevant academic research and scientific papers

MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)

The present invention relates to compounds of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof that are useful as modulators of STING (Stimulator of Interferon Genes). The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds.

Aminophosphate functionalized ionic liquid and preparation method and application thereof

The invention discloses an aminophosphate functionalized ionic liquid and a preparation method and application thereof. The aminophosphate functionalized ionic liquid is characterized in that imidazole is taken as a cationic substrate of an ionic liquid, and aminophosphate is introduced onto the side chain of imidazole to realize synthesis of the aminophosphate functionalized ionic liquid. The phosphate functional group in the functionalized ionic liquid is linked with an imidazolium cation through an aminoalkyl chain, and phosphate and amino have coordination effects on uranyl metal ions, so that the problem of low uranyl extraction efficiency of the conventional TBP-functionalized ionic liquid is solved. The aminophosphate functionalized ionic liquid provided by the invention can serve as an efficient extraction agent to be used in the field of extraction and spent fuel after-treatment of the uranyl metal ions, and has the advantages that the extraction efficiency is high, and one-time uranyl extraction rate can be up to 99.88%.

The first potent inhibitors for human glutaminyl cyclase: Synthesis and structure-activity relationship

The first effective inhibitors for human glutaminyl cyclase (QC) are described. The structures are developed by applying a ligand-based optimization approach starting from imidazole. Screening of derivatives of that heterocycle led to compounds of the imidazol-1-yl-alkyl thiourea type as a lead scaffold. A library of thiourea derivatives was synthesized, resulting in an inhibitory improvement by 2 orders of magnitude, leading to 1-(3-(1H-imidazol-1-yl)propyl)- 3-(3,4-dimethoxyphenyl)thiourea as a potent inhibitor. Systematic exploitation of the scaffold revealed a strong impact on the inhibitory efficacy and resulted in the development of imidazole-propyl-thioamides as another new class of potent inhibitors. A flexible alignment of the most potent compounds of the thioamide and thiourea class and a QC substrate revealed a good match of characteristic features of the molecules, which suggests a similar binding mode of both inhibitors and the substrate to the active site of QC.

Therapeutic agents useful for treating inflammatory diseases

This invention relates to compounds of formula I and pharmaceutically acceptable salts thereof STR1 in which R1, R2 and R3 independently represent hydrogen, halo, alkyl, alkoxy, phenoxy, phenyl, alkoxycarbonyl, --NR13 R14, halogenated alkoxy, halogenated alkyl, benzyloxy, hydroxy, hydroxyalkyl, (C2-6 alkoxycarbonyl)vinyl, --S(O)n R7, carbamoylalkyl, alkoxycarbonylalkyl, --CONR11 R12, or R1 and R2 together with the phenyl ring represent a naphthyl group; R4 and R5 independently represent hydrogen, alkyl, phenyl or together with the carbon atom represent C3-6 cycloalkyl; R6 represents hydrogen, alkyl or ω-hydroxy alkyl; A represents C2-9 alkylene; R8 represents hydrogen, alkyl, halo, alkoxy, hydroxyalkyl, benzyl or phenyl; R9 and R10 independently represent hydrogen, alkyl, halo, alkoxy, phenyl, hydroxyalkyl, alkoxycarbonyl, nitro, --NR30 R31, alkanoyloxyalkyl, or aminomethyl; which are antiinflammatory and antiallergic agents. Compositions containing these compounds and processes to make them are also disclosed.

2-heteroaryl-alkyl-1H-benz[de]-isoquinoline-1,3(2H)-diones

This invention concerns novel 2-heteroarylalkyl-1H-benz[de]isoquinoline-1,3(2H)-diones which are useful as inhibitors of thromboxane synthetase and/or as hypotensive agents in the treatment of hypertension and myocardial ischemia.

N-(Heterocyclic alkyl)pyridoquinazoline-8-carboxamides as Orally Active Antiallergy Agents

A series of N-(heterocyclic alkyl)pyridoquinazoline-8-carboxamides were evaluated for their ability to antagonize slow-reacting substance of anaphylaxis (SRS-A) induced contractions of guinea pig ilea and to inhibit thromboxane synthase in vitro.The results indicated that those pyridoquinazoline-8-carboxamides bearing a branched-chain alkyl moiety in the 2-position and a four to six atom linear chain between a 3- or 4-substituted pyridine or a 1-substituted imidazole ring and the carboxamide nitrogen atom showed the best combination of potencies in the two assays.Several of these compounds were found to be orally active inhibitors of LTE4-induced bronchoconstriction in the guinea pig and LTE4-induced skin wheal formation in the rat.One of the most potent analogues, 2-(1-methylethyl)-N-(1H-imidazol-1-ylbutyl)-11-oxo-11H-pyridoquinazoline-8-carboxamide (36), was selected for extensive pharmacological investigation.It was found that this compound was not a specific inhibitor of LTE4-induced symptomatology, but exhibited more general activity by inhibiting bronchospasm in guinea pigs induced by LTC4, LTD4, PAF, and histamine and skin wheal formation in rats and guinea pigs induced by LTC4, LTD4, and PAF.In addition, 36 was orally active in the passive cutaneous anaphylaxis assay, suggesting that it also exhibits mediator release inhibitory activity.On the basis of the overall pharmacological profile of 36 and its closely related analogues, it was concluded that these compounds may be useful for the treatment of asthma.

N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical compositions

This disclosure describes novel N-[ω-(1H-imidazol-1-yl)alkyl]arylamides which possess the property of inhibiting the enzyme thromboxane synthetase and are also useful in the treatment of hypertension and myocardial ischemia.

N-[(1H-imidazol-1-yl)alkyl]-1H-indolecarboxamides useful as thromboxane synthetase inhibitors and antihypertensive agents

This invention discloses novel N-[(1H-imidazol-1-yl)alkyl]-1H-indolecarboxamides which are useful as inhibitors of thromboxane synthetase and/or as antihypertensive agents in the treatment of hypertension and myocardial ischemia.

N-(Substituted phenyl)-N'-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]ureas

N-(Substituted phenyl)-N'-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]ureas which are inhibitors of thromboxane synthetase enzyme.

N-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)-alkyl]benzenesulfonamides and thromboxane synthetase/antihypertensive compositions

This invention concerns novel N-[(1H-imidazol-1-yl), (1H-1,2,4-triazol-1-yl) and (3-pyridyl)alkyl]benzenesulfonamides which are useful as inhibitors of thromboxane synthetase enzyme and/or as antihypertensive agents.